For instance, ATRX loss of function events are associated with specific clusters and may confer sensitivity to ATR inhibition55, which is under clinical investigation as a therapeutic strategy in sarcomas (NCT03718091, NCT05071209, NCT04807816). This evidence concerns the gene ATRX and sarcoma.